Abstract:Objective: To test whether cerebrospinal fluid (CSF) α-synuclein is altered in Alzheimer’s disease (AD) and different AD pathophysiological profiles based on “ATN” classifications and whether it associated with other AD biomarkers, cognitive decline and imaging evidence of neurodegeneration. Background: More than 50% sporadic AD patients exhibit accumulation of α-synuclein in their brains. CSF α-synuclein could be a potential biomarker of AD. Design/Methods: This prospective case-control study included 385 subjects: 109 cognitively healthy controls, 117 patients with stable mild cognitive impairment (sMCI), 68 patients with progressive mild cognitive impairment (pMCI) and 91 patients with AD dementia from the Alzheimer’s disease Neuroimaging Initiative. The study dates were September 2005, to December 2011. Associations were investigated between CSF α-synuclein and diagnosis, Aβ/tau pathologic features, cognition, brain structure and metabolism. Results: CSF α-synuclein concentration was significantly higher in the AD and pMCI groups compared with the cognitively normal group (P Conclusions: CSF α-synuclein is associated with AD diagnosis and with CSF tau levels, cognition and imaging evidence of neurodegeneration of the disease. This finding implies usefulness for CSF α-synuclein as a potential biomarker for AD. Study Supported by: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI)(National Institutes of Health Grant U01 AG024904) and DOD ADNI(Department of Defense award number W81XWH-12-2-0012). ADNIis funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euro Immun; and F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare;; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research u0026 Development, LLC.; Johnson u0026 Johnson Pharmaceutical Research u0026 Development LLC.; Medpace, Inc.; MerckC Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California Disclosure: Dr. Li has nothing to disclose. Dr. Yu has nothing to disclose. Dr. Tan has nothing to disclose.

Association of cigarette smoking with cerebrospinal fluid biomarkers of insulin sensitivity and neurodegeneration

A Cross‐Sectional Study on Cerebrospinal Fluid Biomarker Levels in Cognitively Normal Elderly Subjects with or Without a Family History of Alzheimer's Disease

Tau Pathologies Mediate the Association of Cigarette Smoking with Cognitive Impairment in Older Adults Without Dementia: The CABLE Study

A history of cigarette smoking is associated with faster functional decline and reduction of entorhinal cortex volume in mild cognitive impairment

Changes metabolic hormones and trace elements in CSF in active smokers indicate oxidative damage to brain cells

Association of Cigarette Smoking With Male Cognitive Impairment and Metal Ions in Cerebrospinal Fluid

Distinct Alteration Patterns of Resting-State Functional Connectivity of the Corticostriatal Circuits Effected by Cigarette Smoking in Mild Cognitive Impairment Patients and Cognitively Normal subjects

CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly

Fasting Blood Glucose and Cerebrospinal Fluid Alzheimer's Biomarkers in Non-Diabetic Cognitively Normal Elders: the CABLE Study.

29 Smoking as a Risk Factor: Altered Brain Activity in Areas Associated with Preclinical Alzheimer's Disease

Distinct resting-state functional connectivity patterns of Anterior Insula affected by smoking in mild cognitive impairment

Cerebrospinal fluid α-synuclein as a potential biomarker for Alzheimer’s disease (P4.174)

Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: the CABLE Study.

Interactions between cigarette smoking and cognitive status on functional connectivity of the cortico-striatal circuits in individuals without dementia: A resting-state functional MRI study

Changes in Cerebrospinal Fluid Tau and Β-Amyloid Levels in Diabetic and Prediabetic Patients: A Meta-Analysis

Peripheral Blood Biomarkers CXCL12 and TNFRSF13C Associate with Cerebrospinal Fluid Biomarkers and Infiltrating Immune Cells in Alzheimer Disease

Alzheimer's disease pathology: pathways between chronic vascular risk factors and blood-brain barrier dysfunction in a cohort of patients with different types of dementia

Association of Cerebrospinal Fluid Neurogranin Levels with Cognition and Neurodegeneration in Alzheimer's Disease

Plasma Insulin Predicts Early Amyloid-β Pathology Changes in Alzheimer's Disease

Effects of insulin on transcriptional response and permeability in an in vitro model of human blood-brain barrier

Association of Smoking Using with ALS Risk and Prognosis in China